Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

This Phase 3 study compares two chemotherapy regimens, each combined with the immunotherapy drug camrelizumab, in patients with high-risk nasopharyngeal carcinoma (a cancer of the back of the nose and throat) that has spread to lymph nodes. The goal is to find the best combination treatment before radiation therapy. **You may be eligible if...** - You have a confirmed diagnosis of nasopharyngeal carcinoma (WHO type II or III) - Your cancer is classified as stage TanyN3M0 (spread to distant lymph nodes but not other organs) - You have not received prior treatment for this cancer - You are between 18 and 65 years old - You are in good general health (ECOG performance status 0–1) - Your blood counts, liver function, and kidney function meet study requirements **You may NOT be eligible if...** - You are pregnant or in the perinatal period - You have known allergies to the study drugs - You have severe heart, lung, liver, or kidney dysfunction - You have HIV/AIDS, active hepatitis B or C, or a serious uncontrolled infection - You have a history of another cancer in the past 5 years (except certain treated skin cancers) Talk to your doctor to see if this trial is right for you.